[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-338096-105":59,"doc-detail-338096-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","the-role-of-immunotherapy-in-the-treatment-of-gynecologic-cancers-a-systematic-review","The Role of Immunotherapy in the Treatment of Gynecologic Cancers - A Systematic Review","","Gynecologic cancers remain a major global health burden, and immunotherapy has become a promising approach across cancer types. This systematic review evaluates the efficacy and safety of immune checkpoint inhibitors, used alone or with other therapies, for gynecologic cancers. Searches across PubMed/MEDLINE, Cochrane Library, Embase, Web of Science, and ClinicalTrials.gov included randomized controlled trials and prospective studies. Study quality was assessed using the MMAT tool and risk of bias tools. Seventeen studies covered ovarian, endometrial, and cervical cancers, showing improved progression-free survival in multiple trials, with generally consistent safety profiles. Further research is needed to optimize patient selection and combination strategies.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/the-role-of-immunotherapy-in-the-treatment-of-gynecologic-cancers-a-systematic-review/338096/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/the-role-of-immunotherapy-in-the-treatment-of-gynecologic-cancers-a-systematic-review/338096.png","ImageObject",300,407,{"name":92,"@type":93},"Asher","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-31","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":39},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What treatment approach does the review focus on for gynecologic cancers?","Question",{"text":112,"@type":113},"The review focuses on immunotherapy, specifically immune checkpoint inhibitors, used alone or in combination with other therapies.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How were the included studies evaluated for quality and bias?",{"text":117,"@type":113},"Study quality was assessed using the MMAT tool, and risk of bias was evaluated using appropriate tools for each study design.",{"name":119,"@type":110,"acceptedAnswer":120},"What outcomes did the review highlight regarding effectiveness and safety?",{"text":121,"@type":113},"Immune checkpoint inhibitors improved progression-free survival across multiple trials, with safety profiles generally consistent with known effects of immunotherapy.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},338096,1790618839,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":39,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":41,"preview_page_count":19,"preview_urls":145},687197207639,"https://ap-avatar.wpscdn.com/davatar_a8503ba1806abce46bf441b54a3ca4cd","Review began 07/19/2024  \nReview ended 07/24/2024  \nPublished 07/29/2024  \n© Copyright 2024  \nFarajimakin. This is an open access article distributed under the terms of the Creative Commons Attribution License CC-BY 4.0. , which permits unrestricted use , distribution , and reproduction in any medium , provided the original author and source are credited.  \nDOI: 10.7759/cureus.65638  \nOpen Access Review Article  \nThe Role of Immunotherapy in the Treatment of Gynecologic Cancers: A Systematic Review  \nOlugbenga Farajimakin 1  \n1. Clinical Research, Faraj-Lab Medical Diagnostics and Research Centre, Lagos, NGA Corresponding author: Olugbenga Farajimakin, [ofarajimakin@gmail.com](ofarajimakin@gmail.com)  \nAbstract  \nGynecologic cancers remain a significant health burden worldwide. Immunotherapy has emerged as a promising treatment approach across various cancer types. To evaluate the efficacy and safety of immune checkpoint inhibitors, alone or in combination with other therapies, in the treatment of gynecologic cancers. We searched PubMed/MEDLINE, Cochrane Library, Embase, Web of Science, [and ClinicalTrials.gov](and ClinicalTrials.gov)[ ](and ClinicalTrials.gov)[for clinical trials of immunotherapy in gynecologic cancers. Randomized controlled trials and prospective](for clinical trials of immunotherapy in gynecologic cancers. Randomized controlled trials and prospective)[ ](for clinical trials of immunotherapy in gynecologic cancers. Randomized controlled trials and prospective)[studies were included. MMAT tool was used to assess the quality of the studies. Risk of bias was assessed](studies were included. MMAT tool was used to assess the quality of the studies. Risk of bias was assessed)[ ](studies were included. MMAT tool was used to assess the quality of the studies. Risk of bias was assessed)[using appropriate tools for each study design. Seventeen studies met inclusion criteria](using appropriate tools for each study design. Seventeen studies met inclusion criteria), encompassing ovarian, endometrial, and cervical cancers. Immune checkpoint inhibitors, particularly in combination with standard therapies, demonstrated improved progression-free survival across multiple trials. Notable results include improved outcomes with pembrolizumab in endometrial and cervical cancers, and promising combinations of PARP inhibitors with checkpoint inhibitors in ovarian cancer. Safety profiles were generally consistent with known effects of immunotherapy. Immunotherapy shows significant promise in improving outcomes for patients with gynecologic cancers. Further research is needed to optimize patient selection and combination strategies.  \nCategories: Preventive Medicine, Epidemiology/Public Health, Allergy/Immunology  \nKeywords: combination therapies, progression-free survival, immune checkpoint inhibitors, immunotherapy, gynecologic cancers  \nIntroduction And Background  \nGynecologic cancers, including malignancies of the ovaries, uterus, cervix, vulva, and vagina, remain a significant challenge in oncology. These cancers contribute substantially to global morbidity and mortality, with ovarian cancer alone causing over 200,000 deaths annually [1,2] . Despite advancements in surgical techniques, chemotherapy regimens, and targeted therapies, many patients experience recurrence or disease progression, underscoring the urgent need for innovative treatment approaches [3] . The intricate relationship between cancer cells and the immune system has long been recognized as a crucial factor in tumor development and progression [4] . In recent years, immunotherapy has emerged as a groundbreaking treatment modality across various cancer types, offering new hope for patients with previously limited options [5] . Immune checkpoint inhibitors (ICIs) have shown remarkable efficacy in several solid tumors by reactivating the body 's immune response against cancer cells [6] .  \nICIs primarily target the programmed cell death protein 1 (PD-1), its ligand","cbCaif6O6lGdaUGI","https://ap.wps.com/l/cbCaif6O6lGdaUGI","pdf",904126,12,"English","# Abstract\n# Introduction And Background\n## Rationale for immunotherapy\n## Mechanisms of immune checkpoint inhibitors\n## Evidence across gynecologic cancer types\n# How to cite this article","[{\"question\":\"What treatment approach does the review focus on for gynecologic cancers?\",\"answer\":\"The review focuses on immunotherapy, specifically immune checkpoint inhibitors, used alone or in combination with other therapies.\"},{\"question\":\"How were the included studies evaluated for quality and bias?\",\"answer\":\"Study quality was assessed using the MMAT tool, and risk of bias was evaluated using appropriate tools for each study design.\"},{\"question\":\"What outcomes did the review highlight regarding effectiveness and safety?\",\"answer\":\"Immune checkpoint inhibitors improved progression-free survival across multiple trials, with safety profiles generally consistent with known effects of immunotherapy.\"}]","The Role of Immunotherapy in the Treatment of Gynecologic Cancers - A Systematic Review | PDF",1790021936,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/4ac6aaccb790e3aadaf21f689066bf76.webp",983,1390,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/6324c18542f12ab39ca1b8abeabee2cc.webp",982,1389,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/8f6f0c54386e17e0a2b41c1b2bb5b6c7.webp",981,1387,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c182066a4b01af674e0451cab51f833a.webp",980,1386]